BBB-Therapeutics B.V.
🇳🇱Netherlands
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
Phase 1
Terminated
- Conditions
- Multiple SclerosisHealthy Volunteers
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- BBB-Therapeutics B.V.
- Target Recruit Count
- 47
- Registration Number
- NCT02048358
- Locations
- 🇳🇱
VUmc, PET and neurology clinical research unit, Amsterdam, Noord-Holland, Netherlands
🇳🇱Centre for Human Drug Research (CHDR), Leiden, Netherlands
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Phase 1
Completed
- Conditions
- Brain MetastasesBreast CancerMelanomaMalignant GliomaLung Cancer
- Interventions
- Drug: 2B3-101 50 mg/m2 every 3 weeksDrug: 2B3-101 60 mg/m2 every 4 weeks
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- BBB-Therapeutics B.V.
- Target Recruit Count
- 84
- Registration Number
- NCT01386580
- Locations
- 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇧🇪Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
🇧🇪Jules Bordet Institute, Brussels, Belgium
News
No news found